Answers are grounded in this paper and cite their sources.
Although guidelines recommend the use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) in patients with diabetes, hypertension, and albuminuria, their use remains suboptimal in several developed countries. Limited data are available on ACEi/ARB use in developing countries. Here, we assessed the use of ACEi/ARB and identified factors contributing to their underutilization at Hatyai Hospital, Thailand.
No takes yet. Share an insight, caveat, or question.
Chienwichai et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: